Switzerland Receives Request For Compulsory Licence On Breast Cancer Drug 01/02/2019 by Intellectual Property Watch 1 Comment Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)By Catherine Saez Swiss health activist group Public Eye yesterday requested the Swiss government to declare a compulsory licence for a Roche breast cancer treatment which the group says is unaffordable. According to Public Eye [pdf – in French], Swiss federal intellectual property law includes the possibility of compulsory licences. The group prepared a compulsory licence file for Perjeta, (chemical name pertuzumab), a Roche blockbuster, and is asking the Swiss Health Minister Alain Berset to forward it to the Swiss patent court. The request for a compulsory licence is available here [pdf]. “Exorbitant” prices of medicines are leading to skyrocketing health costs in Switzerland, and constitute a barrier to access to medicines, according to Public Eye. The breast cancer treatment combining Perjeta, and Herceptin (chemical name trastuzumab), also manufactured by Swiss-based Roche costs CHF 100,000 per year per patient, according to Public Eye, who adds that the Swiss pharmaceutical giant has banked over CHF 2 billion thanks to its Perjeta sales. A compulsory licence could lower the price of the breast cancer treatment, by allowing the production of generic alternatives, the group said. Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related "Switzerland Receives Request For Compulsory Licence On Breast Cancer Drug" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
[…] Switzerland, the activist group Public Eye requested a CL for the medicine Perjeta, a so-called ‘blockbuster drug’ of the Swiss Roche laboratory used in the treatment of breast […] Reply